Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem.

Tanaka A, Takechi K, Watanabe S, Tanaka M, Suemaru K, Araki H.

Int J Clin Pharm. 2013 Oct;35(5):683-7. doi: 10.1007/s11096-013-9799-3. Epub 2013 Jun 4. Erratum in: Int J Clin Pharm. 2015 Jun;37(3):546-7.

PMID:
23733559
2.

Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.

Tanaka A, Takechi K, Watanabe S, Tanaka M, Suemaru K, Araki H.

Antimicrob Agents Chemother. 2014 Aug;58(8):4380-3. doi: 10.1128/AAC.02862-14. Epub 2014 May 19.

3.

Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.

Descombes E, Martins F, Hemett OM, Erard V, Chuard C.

BMC Pharmacol Toxicol. 2016 Feb 4;17:4. doi: 10.1186/s40360-016-0048-y.

4.

Continuous epileptiform discharges in patients treated with cefepime or meropenem.

Naeije G, Lorent S, Vincent JL, Legros B.

Arch Neurol. 2011 Oct;68(10):1303-7. doi: 10.1001/archneurol.2011.204.

PMID:
21987544
5.

When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.

Goff DA, Nicolau DP.

Clin Ther. 2013 Jun;35(6):766-71. doi: 10.1016/j.clinthera.2013.05.004.

PMID:
23795574
6.

[Efficacy and safety of cefepime in the treatment of bronchopulmonary disease exacerbation in pediatric patients with mucoviscidosis].

Semykin SIu, Postnikov SS, Polikarpova SV, Dubovik LG, Kolbatova ES.

Antibiot Khimioter. 2005;50(4):18-22. Russian.

PMID:
16392335
7.

In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K.

Antimicrob Agents Chemother. 2010 Jan;54(1):116-25. doi: 10.1128/AAC.00642-09. Epub 2009 Nov 2.

8.

Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.

Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A; Japan Febrile Neutropenia Study Group.

J Infect Chemother. 2015 Jan;21(1):16-22. doi: 10.1016/j.jiac.2014.08.026. Epub 2014 Sep 17.

PMID:
25239059
10.
11.

The neurotoxicity and safety of treatment with cefepime in patients with renal failure.

Sonck J, Laureys G, Verbeelen D.

Nephrol Dial Transplant. 2008 Mar;23(3):966-70. doi: 10.1093/ndt/gfm713. Epub 2008 Jan 5.

PMID:
18175786
12.

Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.

Diagn Microbiol Infect Dis. 2007 Feb;57(2):153-61. Epub 2006 Aug 23.

PMID:
16930925
13.

Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.

Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2006 Nov;28(5):433-8.

PMID:
17046212
14.

Clinical and electroencephalographic assessment of cefepime during treatment of nosocomial infections in neurological patients.

Alvarez SD, Aragon Mdel C, Moreno A, Palomares-Alonso F, Cook HJ, Cardenas G, Soto-Hernandez JL.

Cent Nerv Syst Agents Med Chem. 2011 Sep 1;11(3):223-7.

PMID:
21919869
15.

Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.

Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, Westervelt P, Ritchie DJ.

Pharmacotherapy. 2009 Aug;29(8):914-23. doi: 10.1592/phco.29.8.914.

17.

Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway.

Kuti JL, Nicolau DP.

J Crit Care. 2010 Mar;25(1):155-6. doi: 10.1016/j.jcrc.2010.01.001. No abstract available.

PMID:
20189057
18.
19.

Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.

Crandon JL, Bulik CC, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2010 Mar;54(3):1111-6. doi: 10.1128/AAC.01183-09. Epub 2009 Dec 28.

20.

Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa.

Nakamura A, Miyake K, Misawa S, Kuno Y, Horii T, Kondo S, Tabe Y, Ohsaka A.

J Hosp Infect. 2013 Feb;83(2):153-5. doi: 10.1016/j.jhin.2012.10.005. Epub 2012 Nov 30.

PMID:
23201400

Supplemental Content

Support Center